#United States #Medical Devices #Nuclear Medicine #International Isotopes #Idaho Falls

International Isotopes Inc. Reports Financial Results for Q1 2025

On May 20, 2025, International Isotopes Inc. (OTCQB: INIS) announced its financial results for the first quarter of the fiscal year 2025. The company experienced promising growth, reporting an increase in overall product sales and improvements in revenue figures compared to the previous year.

Sales Overview

For the first quarter of 2025, International Isotopes generated a total revenue of $3,238,900, which marks a $334,442, or a 12% increase, from the $2,904,458 reported during the same quarter in 2024. This growth in sales is primarily attributed to the remarkable performance in the Nuclear Medicine Standards sector, where sales surged by a substantial 73%, amounting to $1,326,766.

Key Performance Indicators

• - Net Loss: The company's net loss improved significantly to $112,694, a 27% enhancement from a loss of $154,051 in Q1 2024.
• - EBITDA: Non-GAAP EBITDA showed a turnaround, rising to $7,075, representing an increase of 136% from a loss of $19,876 the previous year.
• - Adjusted EBITDA: In contrast, the adjusted EBITDA registered a decline of 55%, totaling $91,611.

Several factors influenced these financial results. A continued supply problem for Theranostics products due to a two-week outage of raw materials hindered sales, while reduced revenue from Cobalt products reflected typical seasonality.

Segment Performance

Theranostics Products

In the first quarter, Theranostics revenue totaled $1,787,054, down 6% from the previous year’s $1,905,082. The downturn is linked to a temporary supply interruption. However, the company is optimistic that FDA approval for additional raw material suppliers will help stabilize future sales.

Nuclear Medicine Standards

The spike in revenue in the Nuclear Medicine Standards was largely due to the alleviation of a long-standing shortage of the Cobalt-57 isotope, which previously affected supply chains. With issues increasingly resolved, sales are expected to normalize.

Cobalt Products

Conversely, sales for Cobalt Products dropped drastically to $72,450 from $233,968, showcasing a 69% decrease. This decline aligns with historical sales patterns where high-activity Cobalt-60 sources are sold at varying times throughout the year.

Medical Devices

A notable new area of growth is the Medical Devices segment, which reported initial revenue of $52,630 in Q1 2025. This sector primarily includes the Swirler® and Tru-Fit™ Mouthpieces and is integral to the company’s expansion strategy.

Future Outlook

Looking ahead, Shahe Bagerdjian, President and CEO of International Isotopes, noted that operational enhancements and product launches remain focal points for the remainder of 2025. Expectations for increased sales of Cobalt products and the introduction of new offerings under the RadQual PET and RadVent lines are set to unfold in the second half of the year.

Investments in the Medical Device area are also anticipated to ramp up, focusing on advancements that enhance safety and efficiency in radiopharmaceutical diagnostics.

Overall, International Isotopes Inc.'s financial report for Q1 2025 underscores the company's potential and its adaptive strategies in a competitive landscape. Investors remain optimistic regarding the planned growth initiatives and product expansions, with several developments set to come to fruition as the year progresses.

For more information about International Isotopes Inc., including further financial disclosure and operational updates, visit their official website.